JP2010502586A - コーヒー酸と誘導体の抗ガン用途 - Google Patents

コーヒー酸と誘導体の抗ガン用途 Download PDF

Info

Publication number
JP2010502586A
JP2010502586A JP2009526219A JP2009526219A JP2010502586A JP 2010502586 A JP2010502586 A JP 2010502586A JP 2009526219 A JP2009526219 A JP 2009526219A JP 2009526219 A JP2009526219 A JP 2009526219A JP 2010502586 A JP2010502586 A JP 2010502586A
Authority
JP
Japan
Prior art keywords
phenyl
dihydroxy
abl
bcr
propenone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009526219A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010502586A5 (enExample
Inventor
カルパナ・サンジャイ・ジョシ
ミーナークシ・シヴァクマール
ヴァルミク・ソパン・アウェア
ヴィラス・サムパトラオ・ワグ
アミット・デシュパンデ
アンクシュ・ガンガラム・サルデ
ソメシュ・シャルマ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Piramal Life Sciences Ltd
Original Assignee
Piramal Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Piramal Life Sciences Ltd filed Critical Piramal Life Sciences Ltd
Publication of JP2010502586A publication Critical patent/JP2010502586A/ja
Publication of JP2010502586A5 publication Critical patent/JP2010502586A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2009526219A 2006-09-01 2007-08-20 コーヒー酸と誘導体の抗ガン用途 Pending JP2010502586A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84206006P 2006-09-01 2006-09-01
PCT/IB2007/053308 WO2008026125A2 (en) 2006-09-01 2007-08-20 Anti cancer use of caffeic acid and derivatives

Publications (2)

Publication Number Publication Date
JP2010502586A true JP2010502586A (ja) 2010-01-28
JP2010502586A5 JP2010502586A5 (enExample) 2010-10-07

Family

ID=39015871

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009526219A Pending JP2010502586A (ja) 2006-09-01 2007-08-20 コーヒー酸と誘導体の抗ガン用途

Country Status (12)

Country Link
US (1) US20100010002A1 (enExample)
EP (1) EP2061452B1 (enExample)
JP (1) JP2010502586A (enExample)
AT (1) ATE530176T1 (enExample)
AU (1) AU2007290960B2 (enExample)
CA (1) CA2662126A1 (enExample)
DK (1) DK2061452T3 (enExample)
ES (1) ES2376277T3 (enExample)
IL (1) IL197262A0 (enExample)
PT (1) PT2061452E (enExample)
TW (1) TW200812955A (enExample)
WO (1) WO2008026125A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8722665B2 (en) 2008-11-07 2014-05-13 Council Of Scientific & Industrial Research Cinnamido-pyrrolo[2,1-C][1,4]benzodiazepines as potential anticancer agents and process for the preparation thereof
CN101456890B (zh) * 2008-12-17 2011-02-02 中南大学 白血病bcr/abl融合基因mRNA的特异性抑制剂
EP2427416B1 (en) 2009-05-04 2016-03-09 Prometic Pharma Smt Limited Substituted aromatic compounds and pharmaceutical uses thereof
BR112012021476A2 (pt) 2010-02-25 2019-09-24 Piramal Entpr Ltd composto, processo para preparação do composto, composição farmacêutica compreendendo uma quantidade terapeuticamente eficaz do composto e emprego de tal composto
CN105997967B (zh) 2010-10-27 2019-08-23 普罗米蒂克医药Smt有限公司 用于治疗癌症的化合物和组合物
US20140127316A1 (en) * 2011-05-20 2014-05-08 New York University Propolis and caffeic acid phenethyl ester and uses thereof
US20160194718A1 (en) * 2013-05-21 2016-07-07 Dana-Farber Cancer Institute, Inc. Compositions and Methods for Identification, Assessment, Prevention, and Treatment of Cancer Using Histone H3K27ME3 Biomarkers and Modulators
WO2017161093A1 (en) * 2016-03-17 2017-09-21 Musc Foundation For Research Development Caffeic acid derivatives and uses thereof
BR112022004890A2 (pt) * 2019-09-17 2022-06-07 Enzene Biosciences Ltd Composições para uso na inibição de src quinase e no tratamento e na prevenção de distúrbios associados
EP4023301A3 (en) * 2020-12-29 2022-09-07 Huscion Co., Ltd. Piperlongumine-based compound and immuno regulator comprising the same
US20240109855A1 (en) * 2021-01-14 2024-04-04 B. G. Negev Technologies And Applications Ltd., At Ben-Gurion University Anti-quorum sensing, anti-biofilm, and inflammation attenuating compounds, compositions, and methods of using same

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040006138A1 (en) * 2002-07-08 2004-01-08 Council Of Scientific Pharmaceutical composition useful for treating chronic myeloid leukemia
WO2005099721A2 (en) * 2004-04-15 2005-10-27 The Regents Of The University Of California Compositions comprising plant-derived polyphenolic compounds and inhibitors of reactive oxygen species and methods of using thereof
JP2006519752A (ja) * 2002-05-31 2006-08-31 カウンシル オブ サイエンティフィク アンド インダストリアル リサーチ 慢性骨髄性白血病を治療するために有用な医薬組成物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5216024A (en) * 1987-07-28 1993-06-01 Baylor College Of Medicine Cell growth inhibitors and methods of treating cancer and cell proliferative diseases
US5008441A (en) * 1987-08-04 1991-04-16 The Trustees Of Columbia University In The City Of New York Caffeic acid esters and methods of producing and using same
DE60206531T2 (de) * 2002-05-31 2006-07-13 Council Of Scientific & Industrial Research Ein kräutermolekül als potentielles anti-leukämisches arzneimittel
US20050282892A1 (en) * 2002-07-08 2005-12-22 Santu Bandyopadhyay Pharmaceutical composition useful for treating chronic myeloid leukemia
US20070161704A1 (en) * 2002-07-08 2007-07-12 Council Of Scientific And Industrial Research Pharmaceutical composition useful for treating chronic myeloid leukemia
US20060045887A1 (en) 2004-08-25 2006-03-02 Gavish-Galilee Bio Applications Ltd. Mushroom extracts having anticancer activity

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006519752A (ja) * 2002-05-31 2006-08-31 カウンシル オブ サイエンティフィク アンド インダストリアル リサーチ 慢性骨髄性白血病を治療するために有用な医薬組成物
US20040006138A1 (en) * 2002-07-08 2004-01-08 Council Of Scientific Pharmaceutical composition useful for treating chronic myeloid leukemia
WO2005099721A2 (en) * 2004-04-15 2005-10-27 The Regents Of The University Of California Compositions comprising plant-derived polyphenolic compounds and inhibitors of reactive oxygen species and methods of using thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6012053459; ＢＡＮＤＹＯＰＡＤＨＹＡＹ，Ｇ．　ｅｔ　ａｌ: Ｂｌｏｏｄ Ｖｏｌ．１０４，　Ｎｏ．８, 2004, ｐ．２５１４-２５２２ *
JPN6012053461; 木村晋也　他: 炎症・再生 Ｖｏｌ．２４，　Ｎｏ．２, 2004, ｐ．１１３-１１７ *

Also Published As

Publication number Publication date
ES2376277T3 (es) 2012-03-12
IL197262A0 (en) 2009-12-24
TW200812955A (en) 2008-03-16
EP2061452A2 (en) 2009-05-27
DK2061452T3 (da) 2012-02-13
AU2007290960A1 (en) 2008-03-06
EP2061452B1 (en) 2011-10-26
WO2008026125A3 (en) 2008-10-02
ATE530176T1 (de) 2011-11-15
PT2061452E (pt) 2012-01-13
AU2007290960B2 (en) 2013-04-18
US20100010002A1 (en) 2010-01-14
CA2662126A1 (en) 2008-03-06
WO2008026125A2 (en) 2008-03-06

Similar Documents

Publication Publication Date Title
JP2010502586A5 (enExample)
AU2007290960B2 (en) Anticancer use of caffeic acid and its derivatives
US8691829B2 (en) Treatment of liver disorders with PI3K inhibitors
US9421211B2 (en) N,N′-diarylurea compounds and N,N′-diarylthiourea compounds as inhibitors of translation initiation
US20220040181A1 (en) Combination therapies
WO2013116786A1 (en) Cdk8/cdk19 selective inhibitors and their use in anti-metastatic and chemopreventative methods for cancer
CN101273989B (zh) 一类小檗胺衍生物及其盐的应用
MX2009000713A (es) Inhibidores de jak para el tratamiento de trastornos mieloproliferativos.
CN110785170B (zh) 脂肪细胞的治疗
US11465978B2 (en) Anthranilic amides and the use thereof
JP5289310B2 (ja) 微小管破壊剤及びそれを含有する癌細胞増殖抑制剤
JP2013515766A (ja) イマチニブジクロロ酢酸塩及びそれを含む抗癌剤組成物
CN106518809A (zh) 丙酮酸脱氢酶激酶抑制剂及其应用
US20060111436A1 (en) Compositions and treatments for modulating kinase and/or HMG-CoA reductase
US20160213729A1 (en) Filipendula vulgaris extract and uses thereof
CN106905185A (zh) 酰肼类ido1抑制剂及其医药用途
JP6865174B2 (ja) Ｅｒｇ癌遺伝子阻害剤としてのアゾフェノール
TWI434680B (zh) 二萜類化合物於治療攝護腺癌之用途
US20170340688A1 (en) Titrated extracts of cynara scolymus and uses thereof
TW200922595A (en) Organic compounds
Lee et al. Anticatabolic effects of morin through the counteraction of interleukin-1β-induced inflammation in rat primary chondrocytes
CN112513000A (zh) 新型联苯衍生物化合物及其用途
EP1667719B1 (en) Treatment of gastrointestinal stromal tumors with imatinib and midostaurin
US20150232456A1 (en) Aurora kinase inhibitors
WO2022020605A1 (en) Treatment of metastasized estrogen receptor positive breast cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100820

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100820

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20120309

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121016

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130115

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130122

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130215

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130312

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20130711

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130903